Immunitybio News - October 2026
🟢 Immunitybio is trading 5% up today after FDA expands Anktiva for papillary-only bladder cancer
Immunitybio is trading 5.05% up at $10.29 alongside the FDA’s October 14, 2026 expansion of Anktiva’s approval. - The significant company-specific milestone...
🟢 Immunitybio is trading 10% up today with broader markets higher; catalyst remains unclear
Immunitybio is trading 10.05% higher at $10.21, with no clear company-specific announcement explaining the October 2 move. - The company is scheduled to...
🟢 Immunitybio is trading 7% up today amid broader market gains
Immunitybio is trading at $9.89, up 6.63%, amid broader market strength. - No clear company-specific announcement explaining the rise surfaced in the...